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Objectives: To estimate the direct total and component medical costs for inpatient 
and outpatient care for patients with schizophrenia in Tianjin, China. MethOds: 
Data were extracted from the Tianjin Urban Employee Basic Medical Insurance data-
base. Patients (N= 2125) who were aged ≥ 18 years, at least 1 diagnosis of schizophre-
nia and 12-month continuous enrollment after their first observed schizophrenia 
diagnosis between 2008 and 2010 were included. Psychiatric-related inpatient and 
outpatient direct medical costs were estimated. Results: During the study period, 
60.8% of patients had at least one inpatient admission and 39.2% used only outpa-
tient services. The mean (± SD) total annual cost for inpatients was $2771.9±2175.6, 
with 88.9% ($2465.4±2022.5) due to non-drug medical costs and 11.1% ($306.6±461.7) 
for medications. Total annual costs for the outpatient only group were $230.6±487.3 
with 4.4% ($10.1±40.8) for non-drug medical costs and 95.6% ($220.5±470.3) for medi-
cations. Antipsychotics accounted for 50.4% of the total annual medication costs 
in the inpatient group and 60.0% in outpatient only group. On average, inpatients 
had 2.2 psychiatric hospitalizations and 2.2 outpatient visits. Outpatient only group 
had 5.9 outpatient visits. The highest costs per psychiatric-related inpatient admis-
sion were general care and non-drug treatment (49.8%), followed by examinations 
(21.6%), bed fee (14.6%), and medications (7.8%). The majority of costs for outpatient 
visits were due to medications (96.2%). cOnclusiOns: Patients who were hospital-
ized for schizophrenia incurred considerably more costs than those who were only 
treated at outpatient setting in Tianjin China, primarily driven by non-drug medical 
care. This suggests that the use of more effective treatments to minimize the risk 
of hospitalization could lead to reduced total health care costs.
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Objectives: To estimate the health care resource utilization and direct medi-
cal costs of patients with schizophrenia in Tianjin, China. MethOds: Data were 
obtained from the Tianjin Urban Employee Basic Medical Insurance database. Adult 
patients with ≥ 1 diagnosis of schizophrenia and 12-month continuous enroll-
ment after the first observed schizophrenia diagnosis between 2008 and 2010 were 
included. Both all-cause and psychiatric-related resource utilization and direct 
medical costs were estimated. Two-sample t-test was used to assess cost differ-
ence. A multiple linear regression model was applied to identify factors associated 
with total cost. Results: A total of 2125 patients were included, with mean age 
of 52.3 years, 49.3% male and 55.7% retired. 60.8% of the patients experienced ≥ 1 
psychiatric-related hospitalizations during the study period. Median (min-max) 
length of stay was 88 (1-365) days per admission and 91 (1-365) days per patient-
year. 58.9% of the patients experienced ≥ 1 psychiatric related outpatient visits. 
Median number of outpatient visits was 4 (1-82). Mean (±SD) total all-cause and 
psychiatric-related direct medical costs were $2863.5±2638.4 and $1774.5±2123.3 
per patient-year respectively, with significant difference between hospitalized and 
non-hospitalized patients ($3953.0 vs. $1176.9, p< 0.001; $2771.9 vs. $230.6, p< 0.001). 
The regression model revealed that patients with more hospitalizations/outpatient 
visits and non-retired patients were more likely to incur higher psychiatric-related 
annual costs. cOnclusiOns: Costs related to treatment with schizophrenia was 
considerable in Tianjin China, driven mainly by psychiatric hospitalizations. Patients 
with psychiatric-related hospitalizations used more medical resources and had 
higher direct medical cost than patients who were not hospitalized.
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Objectives: The economic burden of Alzheimer disease goes beyond the direct 
health cost as the disease has significant economic and social impact on both 
patients themselves and their families (carers). Despite the fact that Greece is 
plagued by the economic crisis, with major cuts in health expenditure, very little 
is known about the cost of chronic diseases and the most cost-effective ways to 
manage them. The study’s’ aim is to estimate, for the first time in Greece, the cost of 
Alzheimer’s disease, per each severity stage, evaluating apart from the direct costs 
of disease, the cost of carers. MethOds: The pilot sample was 46 patients from 
two Alzheimer centers. A cost analysis was conducted from the socio-economic 
perspective. Data regarding the carers’ time were collected via a questionnaire 
developed by the researchers of this study and was partly based on the research 
tool CATS (Caregiver Activities Time Survey) as it was adopted by Jacobsen et al. 
(2011). Results: The total annual cost of the disease was estimated at € 12,140 (SD: 
6,555.9) for the mild stage (MMSE* 30-21), at € 13,735 (SD: 7,858.7) for the moderate 
stage (MMSE 20-11), and € 22,666 (SD: 8,467.2) for the severe stage (MMSE 10-0) (for 
outpatient cases), 87% higher compared to the mild stage of disease. On average, 
from the total cost of disease, 77% was the cost of the primary and the second-
ary caregiver, 8.7% is the cost of medication and 5% is the hospitalization cost. 
Productivity loss of the primary caregiver exceeds 5% of the total cost per patient in 
mild stage. cOnclusiOns: As the patient gets worse and goes from mild to more 
severe stages, the total health care cost increase. It is important, when possible, to 
prolong the stay of patients in the early stages of the disease.
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minimize selection bias. Patients in both groups were required to be at least 18 years 
old, and have continuous medical and pharmacy benefits 1 year pre- and 1 year 
post-index date. One-to-one propensity score matching was applied to compare 
follow-up health care costs and utilizations between patients with and without 
PTSD. Results: A total of 938,138 patients were identified for the PTSD and com-
parison cohorts. After 1:1 matching, a total of 333,303 of patients were matched from 
each group, and baseline characteristics were balanced. Patients diagnosed with 
PTSD used more health care resources for inpatient (8.57% vs. 2.58%, p< 0.01), emer-
gency room (13.45% vs. 7.15%, p< 0.01), physician office (99.59% vs. 55.67%, p< 0.01), 
outpatient (99.64% vs. 56.46%, p< 0.01), and pharmacy visits (89.97% vs. 56.47%, 
p< 0.01) than patients in the comparator cohort. The PTSD cohort also incurred 
higher health care costs for inpatient ($2,587 vs. $719, p< 0.01), emergency room 
($133 vs. $66, p< 0.01), physician office ($3,404 vs. $1,254, p< 0.01), outpatient ($3,735 
vs. $1,430) and pharmacy visits ($629 vs. $362, p< 0.01). cOnclusiOns: Study results 
suggest that the economic burden and health care utilizations were significantly 
higher for patients with PTSD versus those without.
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Objectives: To compare health care costs and utilizations between patients with 
anxiety versus those without in the U.S. veteran population. MethOds: A retro-
spective database analysis was performed using the Veterans Health Administration 
(VHA) Medical SAS datasets (01OCT2008-30SEP2012). Patients diagnosed with anxi-
ety were identified (ICD-9-CM: 300.xx) from October 01, 2009 through September 30, 
2011. The first diagnosis date was designated as the index date for the anxiety group. 
A group of non-anxiety patients of the same age, region, gender and index year 
were identified and matched by baseline Charlson Comorbidity Index (CCI) as the 
comparison group. The index date for the comparator group was randomly chosen 
to reduce the selection bias. Patients in both groups were required to be at least 18 
years old, and have continuous medical and pharmacy benefits 1 year before and 
1 year after the index date. One-to-one propensity score matching was applied to 
compare the health care costs and utilizations during the follow-up period between 
the anxiety and comparison groups, adjusted for baseline demographic and clinical 
characteristics. Results: A total of 928,724 patients were identified for the anxiety 
and comparison cohorts. After 1:1 matching, 338,373 of patients were matched from 
each group and the baseline characteristics were well-balanced. Patients with anxi-
ety had higher percentages of inpatient (11.03% vs. 2.74%, p< 0.01), emergency room 
(18.64% vs. 7.50%, p< 0.01), physician office (99.53% vs. 59.16%, p< 0.01), outpatient 
(99.68% vs. 59.91, p< 0.01) and pharmacy visits (91.42% vs. 59.13%, p< 0.01). The anxi-
ety group had higher expenditures in inpatient ($3,347 vs. $782, p< 0.01), emergency 
room ($204 vs. $68, p< 0.01), physician office ($3,527 vs. $1,435, p< 0.01), outpatient 
($3,948 vs. $1,621) and pharmacy visits ($745 vs. $429, p< 0.01) than the comparison 
group. cOnclusiOns: Results suggest that patients diagnosed with anxiety used 
significantly more health care resources and incurred significantly higher health 
care costs compared to patients without.
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Objectives: Increasing prevalence of dementia highlights the need for a better 
understanding of the cost burden for health policy makers. By descriptive analysis 
of specific cost impacts, cost-of-illness (COI) studies are an essential instrument 
for decision making and planning of health care services. Therefore the purpose of 
this study was to review COI studies of dementia in order to analyze cost compo-
nents and underlying methods in an international context. MethOds: A system-
atic review according to the PRISMA-guidelines was conducted from 2002-2012 in 
order to identify COI studies related to dementia, searching the PubMed, Cochrane, 
EMBASE and NHS Economics Evaluations databases. Annual outcomes per patients 
were analyzed for total, direct, indirect and informal costs. Results: In total 25 
studies were evaluated. Total costs showed an annual range from USD 3.512 to USD 
59.526 in 14 health care systems. This is due to the fact, that the composition of cost 
components and corresponding methods indicated a large heterogeneity in terms 
of both – study characteristics (e.g. diagnosis, care setting, disease stratification) 
and composition of cost components. The majority of studies (92%, n= 23) included 
direct costs, however different cost components and underlying measurements 
were applied. Almost two thirds (60%, n= 15) of the studies included informal costs, 
whereas 9 used the replacement cost approach and 6 studies the opportunity cost 
approach. cOnclusiOns: Outcomes of COI studies in dementia indicate a large 
range, due to differences in health care systems, but also because of methodo-
logical approaches and cost components included. Dementia as a long-lasting and 
progressive disease affects multiple cost dimensions and thereby poses a complex 
challenge for policy makers. In addition, international guidelines on cost analysis 
of dementia are lacking. Standards regarding the methodology of COI studies in 
dementia by the scientific community would be useful. Funded by the European 
Commission, ICT-FP7, project-ID-287509.
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PPP to 69,231 US-$ PPP. A co-morbid conduct disorder was reported to be the most 
influential factor for increased health care costs. All CEA analysed psychotherapy 
interventions. While CEA reporting cost per avoided parasuicide event indicated 
favourable incremental cost effectiveness ratios, CEA reporting cost per quality-
adjusted life years (QALY) indicated just weak cost-effectiveness. cOnclusiOns: 
BPD is associated with high costs. Available COI provide a first insight into the 
structure of cost and its predictors. There are no CEA regarding medication for 
BPD. Evidence regarding the cost-effectiveness of psychotherapy interventions is 
ambiguous. Future research should promote the understanding of the economic 
aspects of BPD and determine the societal value of its treatment. In this context 
high methodical standards are particularly important.
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Objectives: To calculate the annual health insurance treatment cost of epilepsy 
disease in Hungary. MethOds: The data derive from the financial database of the 
Hungarian National Health Insurance Fund Administration (NHIFA), the only health 
care financing agency in Hungary. We analyzed the health insurance treatment 
cost and the number of patients for the year 2010. The following cost categories 
were included into the study: out-patient care, in-patient care, CT-MRI, PET, home 
care, transportation, general practitioner, drugs and medical devices. Results: 
The Hungarian National Health Insurance Fund Administration spent 6.341 billion 
Hungarian Forint (HUF) (23.026 million EUR) for the treatment of epilepsy patients. 
The annual average expenditure per patient was 41900 HUF (152.1 EUR) while the 
average expenditure per one inhabitant was 633 HUF (2.3 EUR). Major cost drivers 
were pharmaceuticals (6.3 % of total health insurance costs), general practitioners 
(13.1 %) and acute inpatient care (11.4 %). The number of patients with epilepsy was 
151 per 100000 populations. We found the highest patient number in pharmaceuti-
cal budget (151357 patients), out-patient care (131280 patients) and general practi-
tioners (86704 patients). cOnclusiOns: Epilepsy disease represents a significant 
burden for the health insurance system. Pharmaceutical treatment is the major 
cost driver for epilepsy disease in Hungary.
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Objectives: To compare health care resource utilization (HRU) and costs among 
children/adolescents with attention deficit/hyperactivity disorder (ADHD) in Quebec, 
Canada, who received an atypical antipsychotic (AAP) as either augmentation or 
alternative therapy to stimulant, before vs. after initiating the AAP. MethOds: 
Patients (6–17 years) with ≥ 2 documented ADHD diagnoses (ICD-9 codes: 314.0–
314.9), who used stimulants for ≥ 30 days and either switched to an AAP or aug-
mented stimulants with an AAP, were identified in Quebec’s health care database, 
the Régie de l’assurance maladie du Québec between 03/2007 and 02/2012. Patients 
with a documented diagnosis for which AAPs are indicated were excluded. All-
cause and ADHD-related HRU and costs (from a public payer’s perspective in 2012 
Canadian dollars) were compared between the 6-month period before (pre-index) 
and after (post-index) patients’ first AAP prescription claim. Results: A total of 453 
children/adolescents met the inclusion criteria (54.5% switched from stimulants to 
AAPs and 45.5% augmented stimulants with AAPs). The mean age was 10.4 years 
(SD= 2.5) and 25.4% were female. The most prevalent documented mental comorbidi-
ties in the pre-index period were adjustment reaction (7.1%), anxiety disorder (5.1%), 
and learning disability (4.4%). Risperidone (81.7%) and quetiapine (16.3%) were the 
most common AAPs initiated. Compared to the pre-index period, patients incurred, 
on average, more all-cause outpatient visits and costs (3.2 vs. 4.6; $207 vs. $303), 
prescription fills and costs (13.3 vs. 22.2; $710 vs. $889), total medical costs ($644 vs. 
$1,096), and total health care costs ($1,354 vs. $1,985) (all p< 0.05) during the post-
index period. Similarly, ADHD-related total health care costs ($835 vs. $1,269; p< 0.05) 
were higher during the post-index period; all-cause and ADHD-related total health 
care costs increased by 46.6% and 52.0%, respectively. cOnclusiOns: Children/
adolescents with ADHD, who received an AAP as either augmentation or alternative 
therapy to stimulant, incurred higher HRU and costs after AAP initiation, mostly 
through ADHD-related HRU.
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Objectives: The goal of our research was to assess and calculate the costs of 
antipsychotic treatment of schizophrenia patients in Hungary, using the database 
of the National Health Insurance Fund (NHIF). Based on the results of a recently 
published study using real world data (Bitter et al. 2013.) we focused especially on 
the costs linked to the early medication discontinuation and poor adherence of 
schizophrenia patients. MethOds: In Hungary all medicines which are purchased 
with reimbursement are documented in the centralized register of the NHIF since 
1998. We analyzed the Payer’s database taking into account the time to treatment 
discontinuation results of the Bitter et al. study. We calculated the yearly aver-
age costs of schizophrenia treatment both per patient, and both per substance 
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Objectives: To gather data concerning burden of schizophrenia in seven Central 
and Eastern European (CEE) countries (Croatia, Estonia, Hungary, Poland, Serbia, 
Slovakia, Slovenia) taking into account: epidemiology, clinical guidelines and rec-
ommendations, current standards of care, costs of illness, resource utilisation, 
health-related quality of life (HRQoL), stigmatisation and discrimination related 
to schizophrenia. The project focused on negative symptoms (NS). MethOds: A 
targeted search was performed focused on publications issued from 1995 onwards 
and indexed in the following databases: PubMed, Cochrane Library, and Centre for 
Review and Dissemination. Moreover, searches for literature in local languages 
from each country of interest were conducted. Results: Fourteen reviews related 
to schizophrenia epidemiology were identified and revealed that the mean inci-
dence of schizophrenia varied greatly from 0.04 to 0.58 per 1,000 population and 
lifetime prevalence from 0.4% to 1.4%. At least one negative symptom was found 
to be present in 57.6% of schizophrenia patients and in 50–90% of individuals expe-
riencing their first schizophrenia episode. Primary NS were observed in 10–30% 
of patients. Mortality of schizophrenia patients was greater than in the general 
population (Standardised Mortality Ratio varies between 2.58 and 4.3), potentially 
due to increased suicide risk, effect of illness on lifestyle and environment, and 
side effects of disease treatment. Identified guidelines indicate a role for second-
generation antipsychotics in NS treatment, nevertheless the development of novel 
therapeutic approaches should be pursued actively. Thirty-seven primary publica-
tions identified from the seven CEE countries which relate to HRQoL of patients 
and caregivers revealed that the disease greatly affects HRQoL of hospitalised 
patients and has a significant negative impact on caregivers’ QoL. cOnclusiOns: 
The literature review confirmed that schizophrenia is one of the most common 
and burdensome mental illnesses, with NS present in a relatively large percent-
age of patients.
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Objectives: To assess the excess direct medical costs associated with a diagnosis of 
attention-deficit/hyperactivity disorder (ADHD) in Germany. MethOds: Nordbaden 
is a region in Southwestern Germany with a population of 2.74 million. Regional 
sociodemographics and health care provider density are well understood and reflect, 
with few exceptions, respective national averages. The Nordbaden database cov-
ers the total regional population insured by SHI (2.24 million lives), integrating 
administrative data from the organization of physicians registered with statutory 
health insurance (SHI) and SHI, allowing patient-centered evaluation of health care 
utilization and direct medical cost for years 2003 to 2009. Patients with a diagnosis 
of ADHD were compared to a control group matched by age, gender, and type of 
health insurance within SHI. Here we report on years 2006-2009, as nonpharmaco-
logical therapy-related cost data were not fully available for earlier years. Results: 
Average annual total cost per ADHD patient increased from € 897 in 2006 to € 1,006 in 
2009 (controls, € 261 in 2006 and € 337 in 2009). Cost per patient correlated positively 
with age, and female patients were generally more costly than males (total as well as 
excess costs). Increasing severity and comorbidity were also associated with higher 
costs per patient. Physician services constituted the major cost component (on 
average, overall, € 653 per case in 2009), followed by pharmacological therapy (€ 330 
in 2009). cOnclusiOns: The average excess cost (from the perspective of German 
SHI) per ADHD patient (over all age groups and irrespective of gender, compared 
to matched controls) was € 669 per year in 2009. Extrapolation from the regional to 
the national level suggests annual outpatient treatment costs attributable to ADHD 
in the magnitude of € 500 million (2009), from the payer’s perspective of SHI. This 
estimate compares to total annual expenditures for health services by German SHI 
of € 160 billion in 2009.
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Objectives: The borderline personality disorder (BPD) is a common mental dis-
order. It is frequently associated with various mental co-morbidities and causes a 
fundamental loss of functioning. Furthermore, economically relevant consequences 
such as high utilization of inpatient and emergency room treatment or reduced 
productivity at work have been reported. The aim of this study is to present the 
existing health economic evidence regarding BPD and to point out implications 
for further research. MethOds: We performed a systematic literature search in 
MEDLINE, EMBASE, PsycInfo and NHSEED to identify cost-of-illness studies (COI), 
cost-effectiveness analyses (CEA) and other cost studies (OCS) regarding BPD. Cost 
data were inflated to the year 2010 and converted into US-$ using purchasing power 
parities (PPP). Quality assessment of the studies was performed by means of a 
standardised quality checklist. Results: We identified three COI, eight CEA and 
six OCS. The methodical quality was moderate. Depending on study perspective 
and considered cost categories cost per patient and year ranged from 18,306 US-$ 
